1. Scrip
  2. >>Business

Podcast: Zydus Lifesciences MD On Rare Disease Focus, Outcomes-Based Digital Transformation

Preparing For A VUCA World

 
• By Vibha Ravi

Zydus Lifesciences is building a rare disease-focused pipeline as a differentiating strategy, managing director Sharvil Patel tells Scrip in an interview. Innovation and patient centricity at heart, digital initiatives are being implemented to transform the company into a ‘future ready’ healthcare organization

Scrip Podcast Special
An Audio Interview With Zydus Lifesciences Managing Director Sharvil Patel

“If we don’t change, we don’t grow” said American author and journalist Gail Sheehy. In February, Zydus Cadila (Cadila Healthcare Ltd) shed a 27-year-old identity to emerge as Zydus Lifesciences Ltd, with managing director Sharvil Patel steering an organizational change that sets course for its growth over the next 25 years.

In an interview with Scrip, Patel says at the heart of this transformation is a desire to produce meaningful outcomes “beyond just pills” for patients via innovation and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.